Oncorus Inc. logo

Oncorus (ONCR) stock

ONCR · Oncorus Inc. · NASDAQ

$0.12-0.01 (-10.15%)today
Alert me next time ONCR moves like this
Website
Open
$0.1261
Prev close
$0.13
VWAP
$0.1277

What is the latest news on ONCR stock?

SECago
SEC Form DEFA14A filed by Oncorus Inc.

DEFA14A - Oncorus, Inc. (0001671818) (Filer)

All ONCR news

When does Oncorus report earnings?

The latest Oncorus earnings release came out on Nov 30, 2022: Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer. Before that, Oncorus reported on Nov 12, 2021.

ONCR earnings history

Latest news

25 items

Oncorus Inc. (ONCR) is a Medicinal Chemicals and Botanical Products company listed on NASDAQ. There were no new wire items for ONCR in the last 30 days. The most recent was published Aug 7, 2023.

Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

ONCR FAQ

6 questions
  • What does Oncorus Inc. do?
    Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial...
  • Where does ONCR stock trade?
    Oncorus Inc. (ONCR) is listed on NASDAQ.
  • What sector and industry is ONCR in?
    Oncorus Inc. operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.
  • When did Oncorus Inc. go public?
    Oncorus Inc. (ONCR) completed its IPO in 2020.
  • What companies are similar to ONCR?
    Notable peers in the same industry include SMFL (Smart for Life Inc.), VLON (Vallon Pharmaceuticals Inc.), MNMD (Mind Medicine (MindMed) Inc.), GRPH (Graphite Bio Inc.), SISI (Shineco Inc.). Compare ONCR side-by-side with any of them on Quantisnow.
  • How can I track ONCR on Quantisnow?
    Quantisnow aggregates Oncorus Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ONCR to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change